UNITY BIOTECHNOLOGY INC (UBX)
US91381U2006 - Common Stock
UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME
UBX Stock Earnings: Unity Biotechnology Beats EPS for Q4 2023
UBX stock results show that Unity Biotechnology beat analyst estimates for earnings per share the fourth quarter of 2023.
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates....
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing...
10 Supplements for Longevity and Antiaging: Expert Recommendations
In this article, we are going to discuss the 10 Supplements for Longevity and Antiaging: Expert Recommendations. You can skip our detailed analysis and go directly to 5 Supplements for Longevity and Antiaging: Expert Recommendations. The anti-aging and longevity market is undergoing a fascinating transformation, driven by personalized approaches, cutting-edge science, and a growing emphasis on evidence-based […]
UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME
Topline 16-week data expected in the fourth quarter of 2024
Unity Biotechnology files to sell 2.27M shares of common stock for holders (NASDAQ:UBX)
Unity Biotechnology has filed a prospectus for the resale of up to 2,271,580 shares of common stock. This is not an offer to sell.
Wedbush upgrades Unity Biotechnology to outperform, cites cash runway (NASDAQ:UBX)
Wedbush upgrades Unity Biotechnology (UBX) to outperform, citing extension of the company's cash runway. Read more here.
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2023.
UNITY Biotechnology to exercise warrants for $4.38M in gross proceeds (NASDAQ:UBX)
UNITY Biotechnology announces exercise of warrants for $4.38 million in gross proceeds, sufficient to fund operations into Q2 2025, and issuance of new...
UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds
Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks
Here are the best longevity stocks to consider. Each stock listed comes with their unique reasons to buy them.
UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
Patients on combination treatment with UBX1325 and aflibercept from weeks 24-48 maintained vision gains achieved at week 24 on aflibercept alone, with...
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing...
UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)
UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)
Phase 2b trial is a randomized, double-masked, active-controlled study designed to evaluate the safety and efficacy of UBX1325 (foselutoclax) compared to...
UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
A single injection of UBX1325 led to a statistically significant and clinically meaningful improvement in Best Corrected Visual Acuity (BCVA) of +6.2 ETDRS...
UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
Program Update with retinal expert and senior clinical advisor Robert B. Bhisitkul, M.D., Ph.D., to be held on Monday, April 24 at 5:00 a.m. PT/8:00 a.m. ET
UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
Program Update with retinal expert and senior clinical advisor Robert B. Bhisitkul, M.D., Ph.D., to be held on Monday, April 24 at 5:00 a.m. ...